Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Public ClinicalTrials.gov record NCT01088984. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of phase 1 of this study is to establish the recommended phase II dose (RP2D). The primary objective of phase 2 of this study is to evaluate the safety and efficacy of bendamustine at the recommended pediatric dose for the treatment of pediatric patients with relapsed or refractory acute leukemia.
Study identification
- NCT ID
- NCT01088984
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 43 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 1 Year to 20 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2010
- Primary completion
- Jul 31, 2011
- Completion
- Jul 31, 2011
- Last update posted
- May 22, 2016
2010 – 2011
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 17 | Orange | California | — | — |
| Teva Investigational Site 12 | San Diego | California | — | — |
| Teva Investigational Site 10 | St. Petersburg | Florida | — | — |
| Teva Investigational Site 8 | Baltimore | Maryland | — | — |
| Teva Investigational Site 16 | Boston | Massachusetts | — | — |
| Teva Investigational Site 9 | Detroit | Michigan | — | — |
| Teva Investigational Site 1 | Jackson | Mississippi | — | — |
| Teva Investigational Site 5 | Kansas City | Missouri | — | — |
| Teva Investigational Site 14 | St Louis | Missouri | — | — |
| Teva Investigational Site 15 | New York | New York | — | — |
| Teva Investigational Site 18 | Portland | Oregon | — | — |
| Teva Investigational Site 11 | Hershey | Pennsylvania | — | — |
| Teva Investigational Site 7 | Philadelphia | Pennsylvania | — | — |
| Teva Investigational Site 19 | Memphis | Tennessee | — | — |
| Teva Investigational Site 3 | Dallas | Texas | — | — |
| Teva Investigational Site 4 | Fort Worth | Texas | — | — |
| Teva Investigational Site 13 | Houston | Texas | — | — |
| Teva Investigational Site 2 | Seattle | Washington | — | — |
| Teva Investigational Site 6 | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01088984, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 22, 2016 · Synced Sep 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01088984 live on ClinicalTrials.gov.